Abstract:Contrast-enhanced magnetic resonance imaging (MRI) of the liver and pancreas is frequently performed to improve the sensitivity and specificity of lesion detection in these organs. The concept of using tissue-specific contrast media is to selectively enhance the normal parenchyma, but not lesions, so that the contrast between tumorous and normal tissue is increased, and lesion detectability improved. Mangafodipir trisodium (MnDPDP) has been developed as a hepatocellular-specific contrast agent, but uptake has also been found in pancreatic tissue. In this study the safety and diagnostic efficacy of MnDPDP were investigated in both healthy volunteers and in patients with liver and pancreatic tumors. In healthy volunteers (n = 8), dose-dependent enhancement in T1-weighted images was observed in the normal liver and pancreatic parenchyma after infusion of MnDPDP at doses of 5 and 10 mumol/kg. The maximal enhancement in the two dose groups was 77 and 110% in the liver, and 57 and 84% in the pancreas, respectively. The enhancement-over-time profiles demonstrated that the effective imaging window was about 2 h for the liver, and over 4 h for the pancreas. There was no measurable enhancement in brain structures protected by intact blood-brain barrier, and no changes of clinical importance were found in vital signs or in blood and urinary chemistry variables. Compared with unenhanced images (including T2-weighted images), significantly more lesions were detected on MnDPDP-enhanced T1 images in 82 patients with liver tumors (mostly metastases). Features such as rim enhancement and the enhancement in hepatocellular carcinomas can provide information for differential diagnosis. In a study on patients with pancreatic tumors, mainly adenocarcinomas (n = 21) and islet cell tumors (n = 19), two additional lesions were found in the MnDPDP-enhanced images. The contrast enhancement in the pancreatic parenchyma can vary greatly, depending on the site of the enhancing part of the organ in relation to a large tumor. The tumors of both origins were also enhanced post-contrast, but to a lesser degree than the normal pancreatic tissue. MnDPDP enhancement was investigated in 30 liver metastases from endocrine tumors in 13 patients. These lesions showed a signal increase of about 49% post-contrast, which lasted longer than that in the normal liver tissue. The findings may help to distinguish these tumors from other metastatic tumors. T1-weighted sequences of four types, including a spin-echo and three variants of fast gradient-echo sequences, and various parameter combinations, were investigated in healthy volunteers (n = 6), with the aim of finding the optimal sequence for MnDPDP-enhanced MRI of the liver and pancreas. The fat-and-water out-of-phase, fast field (gradient)-echo sequence was the best for imaging of both the liver and pancreas. The studies have shown that MnDPDP is safe when given as an infusion, and is effective as a liver- and pancreas-specific contrast medium, with improved lesion detection in MRI of these organs. It is also useful for the characterization of liver tumors.

Manganese-Enhanced Mri Of Hypoxic-Ischemic Brain Injuries Using Mn-Dpdp

Manganese-Enhanced Mri Detection of Neuro Degeneration in Neonatal Hypoxic-Ischemic Cerebral Injury

MnDPDP: Contrast Agent for Imaging and Protection of Viable Tissue

Manganese-Enhanced T1 Mapping in the Myocardium of Normal and Infarcted Hearts

Synthesis of PEG-Coated, Ultrasmall, Manganese-Doped Iron Oxide Nanoparticles with High Relaxivity for T1/T2 Dual-Contrast Magnetic Resonance Imaging

Mangafodipir Trisodium (Mndpdp)-Enhanced Magnetic Resonance Imaging of the Liver and Pancreas.

Manganese-Enhanced Magnetic Resonance Imaging of the Heart

Mn-citrate and Mn-HIDA: intermediate-affinity chelates for manganese-enhanced MRI

Manganese-Loaded Dual-Mesoporous Silica Spheres for Efficient T1- and T2-Weighted Dual Mode Magnetic Resonance Imaging

Zwitterion-Coated Ultrasmall MnO Nanoparticles Enable Highly Sensitive T 1 -Weighted Contrast-Enhanced Brain Imaging

Dose Response and Time Course of Manganese-Enhanced Magnetic Resonance Imaging for Visual Pathway Tracing in Vivo

Assessment of stunned and viable myocardium using manganese-enhanced MRI

Manganese-Enhanced Magnetic Resonance Imaging: Application in Central Nervous System Diseases

Detection of Rat Brain Function by Manganese-enhanced MRI

Contrast-Enhanced Cardiac Magnetic Resonance Imaging With a Manganese-Based Alternative to Gadolinium for Tissue Characterization of Acute Myocardial Infarction

Tracing Neuronal Tracts in the Olfactory Pathway of Rat and Detecting Ischemic Core in a Rat Model of Focal Ischemia Using Manganese Enhanced Magnetic Resonance Imaging

Progress in research of magnetic resonance imaging of manganese contrast agent

Accurate Identification of Myocardial Viability after Myocardial Infarction with Novel Manganese Chelate-Based MR Imaging.

Preparation of Mn2+@PolyDOPA-b-polysarcosine Micelle As MRI Contrast Agent with High Longitudinal Relaxivity

Abstract TP290: A Pilot Study of a Novel Brain Penetrant Mn(III) Porphyrin-Based Sod Mimic on Middle Cerebral Artery Occlusion in Female and Male Mice